Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

24.91 -0.24 (-0.95%)

Official Closing Price Updated: 7:00 PM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Regeneron Pharmaceuticals Q2 Earnings Call Highlights ↗

Today 15:04 EDT

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP...

Via MarketBeat

Topics ETFs Earnings

Regency Centers Q2 Earnings Call Highlights ↗

Today 15:04 EDT

Regency Centers (NASDAQ:REG) reported second-quarter operating momentum marked by higher occupancy, rent growth and an expanded development pipeline, prompting the grocery-anchored shopping center...

Via MarketBeat

Topics ETFs Earnings

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials ↗

Today 12:04 EDT

Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.

Via Benzinga

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗

July 29, 2026

AbbVie still looks like a compelling buy at its all-time high.

Via The Motley Fool

Topics Intellectual Property

Global Oral Contraceptive Drugs Market Growing at 7.3% CAGR Through 2034 ↗

July 29, 2026

According to a new report from Intel Market Research, the global Oral Contraceptive Drugs market was valued at USD 12.9 billion in 2024 and is projected to

Via Talk Markets

GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out' ↗

July 27, 2026

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion Pfizer COVID-19 vaccine contract.

Via Benzinga

Topics Government

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

July 26, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Absurdly Cheap Dividend Stocks to Buy Before August ↗

July 26, 2026

Far from "yield traps," these high-yield dividend stocks represent good value at current prices.

Via The Motley Fool

Topics Artificial Intelligence

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. ↗

July 25, 2026

Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?

Via The Motley Fool

3 Healthcare Stocks We Keep Off Our Radar

July 24, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Via StockStory

BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗

July 23, 2026

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Via The Motley Fool

Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer ↗

July 23, 2026

Income seekers shouldn't give up on the stock yet.

Via The Motley Fool

3 Healthcare Stocks with Competitive Advantages

July 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell. ↗

July 22, 2026

A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring.

Via The Motley Fool

Topics Economy

Pfizer Suspends Popular Menopause Cream in India ↗

July 20, 2026

A Premarin shortage in India leaves menopausal patients facing limited treatment options as Pfizer halts cream distribution.

Via Benzinga

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗

July 20, 2026

It is definitely a strong contender.

Via The Motley Fool

Topics Intellectual Property

3 Unpopular Stocks We’re Skeptical Of

July 20, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

1 Stock Under $50 to Target This Week and 2 We Question

July 20, 2026

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Via StockStory

Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now ↗

July 19, 2026

Pfizer is a highly respected drug company facing normal industry headwinds.

Via The Motley Fool

Topics Intellectual Property

Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? ↗

July 18, 2026

Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut.

Via The Motley Fool

Topics Intellectual Property

Curious about the most active S&P500 stocks in today's session? ↗

July 17, 2026

Via Chartmill

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

All three can be bought on the dip.

Via The Motley Fool

Topics Intellectual Property

Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. ↗

July 16, 2026

Via Chartmill

3 of the Best Stocks to Buy for Less Than $100 Right Now ↗

July 14, 2026

These stocks offer a good mix of dividends, growth, and long-term stability.

Via The Motley Fool

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried? ↗

July 14, 2026

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

Via The Motley Fool

Topics Intellectual Property Stocks

Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗

July 14, 2026

Cathie Wood's biotech ETF has largely moved on from the vaccine maker.

Via The Motley Fool

Topics ETFs

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb ↗

July 14, 2026

Drug pricing matters, but pipelines matter even more.

Via The Motley Fool

Topics Government Intellectual Property

Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗

July 13, 2026

Via Chartmill

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

July 13, 2026

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

Via MarketBeat

2 Value Stocks Worth Your Attention and 1 Facing Headwinds

July 13, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.